Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation

American Journal of the Medical Sciences

Volumn 348, Issue 6, 2014, Pages 513-521

  Sen, Souvik ^a   Dahlberg, Katherine Willett ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Oral anticoagulants; Stroke

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL TRIAL (TOPIC); FEAR; HEART ATRIUM FIBRILLATION; HUMAN; NONVALVULAR ATRIAL FIBRILLATION; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICIAN; PHYSICIAN ATTITUDE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); UPPER GASTROINTESTINAL BLEEDING;

EID: 84916224197     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000349     Document Type: Review

References (78)

1. Rowan SB, Bailey DN, Bublitz CE, et al. Trends in anticoagulation for atrial fibrillation in the US. J Am Coll Cardiol 2007;49:1561-5.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
3. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010;123: 638-45.
4. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013;127:143-52.
5. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006;37:577-617.
6. Freeman WD, Aguilar MI. Prevention of cardioembolic stroke. Neurotherapeutics 2011;8:488-502.
7. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-72.
8. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006;114:e257-354.
9. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). Circulation 2011;123:1144-50.
10. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:7S-47S.
11. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-100.
12. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401.
13. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92.
14. Waldo AL, Becker RC, Tapson VF, et al; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005;46:1729-36.
15. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-34.
16. Hylek EM, D'Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006;37:1075-80.
17. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006;37:1070-4.
18. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm 2008;5:1365-72.
19. Williams CJ, Reynolds MW, Sander SD, et al. The extent of warfarin use and its effectiveness within atrial fibrillation patients from a US nationally representative sample. Presented at: American College of Cardiology 58th Annual Scientific Session; March 29-31, 2009; Orlando, FL.
20. Nieuwlaat R, Capucci A, Lip GYH, et al. Antithrombotic treatment in real-life atrial fibrillation patients: A report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006;27:3018-26.
21. Fitch K, Broulette J, Penson BS, et al. Utilization of anticoagulant therapy in Medicare patients with nonvalvular atrial fibrillation. Am Health Drug Benefits 2012;5:157-68.
22. Murphy MF. Warfarin utilization in Medicare patients with nonvalvular atrial fibrillation: sentinel data from an administrative claims base. Am Health Drug Benefits 2012;5:167-8.
23. Schulman S, Beyth RJ. Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. Eur Heart J Suppl 2005;7(suppl C): C34-40.
24. Mohr JP, Albers GW, Amarenco P, et al. American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Etiology of stroke. Stroke 1997;28:1501-6.
25. Garcia DA, Witt DM, Hylek E, et al. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother 2008;42:979-88.
26. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167:1414-9.
27. Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005;21:1583-94.
28. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001;323: 1218-22.
29. Gattellari M, Worthington J, Zwar N, et al. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: A representative survey of Australian family physicians. Stroke 2008;39:227-30.
30. Choudhry NK, Anderson GM, Laupacis A, et al. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006;332:141-5.
31. Goldstein JN, Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage? Cleve Clin J Med 2010;77:791-9.
32. Katsnelson M, Sacco RL, Moscucci M. Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants. Circulation 2012;125:1577-83.
33. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995;26:1471-7.
34. Freeman WD, Aguilar M. Anticoagulation therapy for cardioembolic stroke prevention in the elderly: defining benefits and risks. Aging Health 2010;6:439-50.
35. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 2003;163:1580-6.
36. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients who are at risk for falls. Arch Intern Med 1999;159:677-85.
37. Delaney JA, Opatrny L, Brophy JM, et al. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007;177:347-51.
38. Hernández-Díaz S, García Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med 2000;160:2093-9.
39. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduced serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
40. Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiiflammatory drugs. N Engl J Med 1998;338:719-26.
41. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282:1929-33.
42. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal bleeding in older persons with atrial fibrillation. Arch Intern Med 2002;162:541-50.
43. Goldhaber SZ. What's the "go to" anticoagulant for stroke prevention in atrial fibrillation? Thromb Haemost 2012;107:397-8.
44. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2011;57:e101-98.
45. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
46. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(suppl 6):381S-453S.
47. Gage BF, Birman-Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005;118:612-7.
48. Jacobs LG, Billett HH, Freeman K, et al. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: A single-center, retrospective observational study. Am J Geriatr Pharmacother 2009;7:159-66.
49. Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a "real world" atrial fibrillation population. Thromb Haemost 2012;107:584-9.
50. Roob G, Lechner A, Schmidt R, et al. Frequency and location of microbleeds in patients with primary intracerebral hemorrhage. Stroke 2000;31:2665-9.
51. Chapman N, Huxley R, Anderson C, et al. Effects of a perindoprilbased blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: The PROGRESS Trial. Stroke 2004;35:116-21.
52. Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: A science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012;43:3442-53.
53. Beasley BN, Unger EF, Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011;364:1788-90.
54. U.S. Food and Drug Administration. Summary Minutes of the Cardiovascular and Renal Drugs Committee. 2010. Available at: www.fda.gov/downloads/Advisory%20Committees/CommitteesMeetingMaterials/%20Drugs/CardiovascularandRenalDrugs%20AdvisoryCommittee/UCM236322. pdf. Accessed December 5, 2012.
55. Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014;113:662-8.
56. Glund S, Stangier J, Schmohl M, et al. A specific antidote for Dabigatran: Immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Dallas, TX: American Heart Association (AHA) 2013 Scientific Sessions; 2013.
57. Crowther M, Vandana M, Michael K, Genmin L, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in Healthy subjects by Andexanet Alfa (PRT064445), an Antidote for Fxa inhibitors. 55th ASJ Annual Meeting and Exposition; November 15, 2013; New Orleans, LA.
58. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165: 1095-106.
59. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154: 1449-57.
60. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: Analysis of pooled data from 3 randomized trials. Arch Intern Med 1997;157:1237-40.
61. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3): 204S-33S.
62. Flockhart DA, O'Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008;10:139-50.
63. Ryan F, Byrne S, O'Shea S. Managing oral anticoagulation therapy: improving clinical outcomes. J Clin Pharm Ther 2008;33:581-90.
64. Ghate SR, Biskupiak J, Ye X, et al. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm 2011;17:672-84.
65. Jacobs JM, Stessman J. New anticoagulant drugs among elderly patients: is caution necessary?: Comment on "The use of dabigatran in elderly patients". Arch Intern Med 2011;171:1287-8.
66. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64.
67. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5(suppl 1):60-4.
68. Weitz JI. Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 2007;5(suppl 1):65-7.
69. U.S. Food and Drug Administration. FDA News Release. October 19, 2010. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed May 2, 2013.
70. U.S. Food and Drug Administration. FDA News Release. November 4, 2011. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm. Accessed May 2, 2013.
71. U.S. Food and Drug Administration. FDA News Release. December 28, 2012. FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm. Accessed May 2, 2013.
72. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
73. Connolly SJ, Ezekowitz MD, Yusuf S, et al; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6.
74. Hart RG, Diener H-C, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran. The RE-LY Trial. Stroke 2012;43:1511-7.
75. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010;64:956-67.
76. Patel MR, Mahaffey KW, Garg J, et al; for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
77. Granger CB, Alexander JH, McMurray JJV, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
78. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.